Walter Flamenbaum MD - 13 Oct 2021 Form 3 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Director
Signature
/s/ Christine Klaskin, attorney-in-fact
Issuer symbol
INKT
Transactions as of
13 Oct 2021
Net transactions value
$0
Form type
3
Filing time
20 Oct 2021, 18:59:52 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding INKT Stock Option (Right to Buy) 13 Oct 2021 Common Stock 166,980 $0.0100 Direct F1
holding INKT Stock Option (Right to Buy) 13 Oct 2021 Common Stock 139,150 $0.0100 Direct F1
holding INKT Stock Option (Right to Buy) 13 Oct 2021 Common Stock 41,745 $3.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The vesting of all such options was accelerated on March 31, 2021 and were fully-vested as of such date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney